ArticleACS omega2026
Optimized Pretreatment and Preparative Chromatography for Vitexin Purification from Mung Bean Seed Coats.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research focuses on the valorization of mung bean hull, a major agro-industrial byproduct, through the development of an optimized process for the high-purity isolation of the bioactive flavonoid, vitexin. Vitexin is recognized for its significant nutraceutical properties, including anticancer, antioxidant, and anti-inflammatory activities, making its high-purity isolation crucial for pharmaceutical and functional food applications. The study emphasized the importance of pretreatment methods to enhance extraction efficiency and downstream purification. Raw material preparation involved controlled grinding and sieving, followed by the selection of a particle size fraction (80-150 mesh) for subsequent pretreatment. This fraction was subjected to a crucial washing step with ethanol to effectively remove residual starch particles. This ethanol washing minimized the loss of vitexin (unlike deionized water washing) and was vital for preventing column clogging and back pressure issues during subsequent chromatographic purification. The optimal solvent extraction condition was determined to be a 50% ethanol/deionized water mixture, which yielded the highest vitexin concentration of 24.29 mg/ga result consistent with tuning the solvent polarity to an optimal dielectric constant (∼45.4) and the effective removal of the starch matrix. For the high-purity purification of vitexin, a Reverse Phase Preparative Liquid Chromatography (Prep-LC) system was utilized. The key operating parametersmobile phase composition and flow ratewere systematically optimized. An initial mobile phase composition of 20:80 acetonitrile:deionized water resulted in poor separation. Fine-tuning the composition to 15:85 acetonitrile:deionized water was critical, achieving the complete baseline separation of vitexin and its isomer, iso-vitexin. The flow rate of 3 mL/min proved to be the optimal compromise, effectively reducing the separation time by approximately 2-fold while maintaining the ability to produce high-purity vitexin (purity ≥ 90%). This study establishes a process-oriented and experimentally validated strategy for producing high-purity vitexin from mung bean hull, integrating effective starch removal and optimized Prep-LC parameters. The identified optimal conditionsextraction with 50% ethanol and purification using Prep-LC with 15:85 acetonitrile:deionized water at 3 mL/minprovide practical operational guidelines that may inform future scale-up studies and process development for vitexin production.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.